Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

121.21 +1.42 (+1.19%)
Streaming Delayed Price Updated: 3:16 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
Via Stocktwits
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
Which S&P500 stocks are moving on Friday?
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes. 
Via Benzinga
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
From Gilead Sciences, Inc.
Via Business Wire
Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
Via Get News
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade. 
Via Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
From Gilead Sciences, Inc.
Via Business Wire
3 S&P 500 Stocks We Approach with Caution
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Intellectual Property Stocks
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
Breaking Down Gilead Sciences: 6 Analysts Share Their Views
 
Via Benzinga
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily
Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investors
Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued. 
Via Chartmill
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway
The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036. 
Via Stocktwits
Topics Intellectual Property
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036. 
Via Benzinga
Topics Intellectual Property
Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEO
The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018. 
Via Investor's Business Daily
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump
The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales. 
Via Investor's Business Daily
Topics Intellectual Property
Discover the top S&P500 movers in Monday's pre-market session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
2 Surefire Dividend Stocks to Buy for the Long Haul
Both have crushed the market in 2025. 
Via The Motley Fool
Topics Economy Government Intellectual Property
Is Gilead Sciences Inc Gaining or Losing Market Support?
 
Via Benzinga
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount. 
Via Benzinga
Market Whales and Their Recent Bets on GILD Options
 
Via Benzinga
2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
Topics Credit Cards
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.